Efficacy and safety of ensitelvir in patients with mild-to-moderate COVID-19: the phase 2b part

Page 1 of 37

1 Article title:

- of a randomized, placebo-controlled, phase 2/3 study
 Authors:
 Hiroshi Mukae¹, Hiroshi Yotsuyanagi², Norio Ohmagari³, Yohei Doi^{4,5}, Hiroki Sakaguchi⁶,
 Takuhiro Sonoyama⁶, Genki Ichihashi⁶, Takao Sanaki⁷, Keiko Baba⁷, Yuko Tsuge⁶, Takeki
 Uehara⁶*
- 9

2

10 **Affiliations:**

- ¹¹ ¹Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical
- 12 Sciences, Nagasaki, Japan
- ¹³ ²The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- ¹⁴ ³Disease Control and Prevention Center, National Center for Global Health and Medicine,
- 15 Tokyo, Japan
- ⁴Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh,
- 17 Pennsylvania, USA
- ⁵Departments of Microbiology and Infectious Diseases, Fujita Health University School of
- 19 Medicine, Toyoake, Japan
- ⁶Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
- ⁷Pharmaceutical Research Division, Shionogi & Co., Ltd., Toyonaka, Japan
- 22

Page 2 of 37

23 ***Corresponding author:**

- 24 Takeki Uehara
- 25 Drug Development and Regulatory Science Division, Shionogi & Co., Ltd.
- 26 Address: 8F, Nissay Yodoyabashi East, 3-3-13 Imabashi, Chuo-ku, Osaka 541-0042, Japan
- 27 Email: <u>takeki.uehara@shionogi.co.jp</u>
- 28 Telephone: +81-6-6209-6907
- 29

Page 3 of 37

30 Abstract

31	This phase 2b part of a randomized phase 2/3 study assessed the efficacy and safety of ensitrelyin
32	for mild-to-moderate coronavirus disease 2019 (COVID-19). Patients were randomized (1:1:1)
33	to orally receive ensiteelvir fumaric acid 125 mg (375 mg on day 1; $n=140$) or 250 mg (750 mg
34	on day 1; $n=140$) or placebo ($n=141$) once daily for 5 days. Compared with placebo, the change
35	from baseline in severe acute respiratory syndrome coronavirus 2 titer (measured as log_{10} 50%
36	tissue-culture infectious dose) on day 4 was significantly greater with ensittelvir 125 mg and
37	250 mg (differences from placebo: -0.41, P<0.0001 for both). The total score of predefined 12
38	COVID-19 symptoms showed an improving trend with ensittelvir treatment without a significant
39	intergroup difference. Most adverse events were mild in severity. Ensitrelvir treatment
40	demonstrated a favorable antiviral efficacy and potential clinical benefit with an acceptable
41	safety profile. (Japan Registry of Clinical Trials identifier: jRCT2031210350)
42	

- 43 **Keywords:** COVID-19, ensitrelvir, S-217622, SARS-CoV-2 3C-like protease inhibitor, viral
- 44 titer

Page 4 of 37

45 Main

46	Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory
47	syndrome coronavirus 2 (SARS-CoV-2), has been declared a global pandemic by the World
48	Health Organization (WHO) (https://www.who.int/emergencies/diseases/novel-coronavirus-
49	2019). As of May 25, 2022, more than 520 million confirmed cases of COVID-19 have been
50	reported worldwide, with over 6 million COVID-19-associated deaths (https://covid19.who.int/).
51	To combat the COVID-19 pandemic, several vaccines against SARS-CoV-2 infection have been
52	developed and approved for clinical use ¹⁻⁴ , and more than 11 billion vaccine doses have been
53	administered to the worldwide population (<u>https://covid19.who.int/</u>). However, humoral immune
54	response against SARS-CoV-2, as measured by neutralizing antibody titers, decreases
55	substantially with time after vaccination ⁵ , potentially leading to postvaccination infections ⁶ .
56	Therefore, in addition to vaccines, effective antiviral agents are needed for the management of
57	the COVID-19 pandemic.
58	Gene mutations in the SARS-CoV-2 genome have resulted in the emergence of various
59	variants, of which those posing an increased risk to global health are referred to as variants of
60	concern (VOCs). The SARS-CoV-2 Omicron (B.1.1.529) variant was first detected in South
61	Africa in November 2021, quickly spread worldwide, and was designated as a VOC by the WHO
62	(https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-
63	variant-of-concern). By the end of January 2022, >99% of SARS-CoV-2 cases reported in the
64	United States (US) had been infected with the Omicron variant ⁷ . This variant is characterized by
65	more than 30 mutations located in its spike protein, of which 15 are focused on the receptor-
66	binding domain ⁸ . Mutations in the receptor-binding domain of the spike protein result in high
67	binding affinity with human angiotensin-converting enzyme 2, increased viral invasion into host

Page 5 of 37

68	cells, and a high transmission rate associated with this VOC ⁹ . The disease caused by infection
69	with the Omicron variant is considered to be less severe than that caused by previous variants ¹⁰⁻
70	¹² , but the high transmissibility and infectivity of this variant may pose an additional threat to
71	global health security. Several antiviral treatment options for patients with COVID-19 at risk of
72	severe disease, including molnupiravir ¹³ , nirmatrelvir in combination with a pharmacokinetic
73	booster ritonavir ¹⁴ , sotrovimab ¹⁵ , and casirivimab/imdevimab ¹⁶ , have demonstrated efficacy in
74	reducing the risk of hospitalization, death, or disease progression. However, in view of the public
75	burden of the transmission of infectious viruses and disease characteristics of COVID-19, as well
76	as to draw maximum benefits from early pharmacological treatment initiation
77	(https://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_drug_220218.pdf; website
78	in Japanese), additional oral antiviral agents that can be administered to patients with
79	mild-to-moderate COVID-19 regardless of the risk of severe disease are needed.
80	Ensitrelvir fumaric acid (S-217622; hereafter, ensitrelvir), a novel oral SARS-CoV-2
81	3C-like protease inhibitor, was discovered through joint research by Hokkaido University and
82	Shionogi & Co., Ltd ¹⁷ . Ensittelvir has shown antiviral efficacy in both <i>in vitro</i> and <i>in vivo</i> animal
83	studies against different SARS-CoV-2 variants, including the Omicron variant ¹⁷⁻¹⁹ . Additionally,
84	in a phase 1 study of ensitrelvir (Japan Registry of Clinical Trials identifier: jRCT2031210202),
85	the once-daily oral dose was well tolerated and demonstrated a favorable pharmacokinetic profile
86	(R. Shimizu, et al., unpublished data). A multicenter, randomized, double-blind,
87	placebo-controlled, phase 2/3 study is also underway to assess the efficacy, safety, and
88	pharmacokinetics of ensitrelvir administered as a 5-day oral regimen. In its phase 2a part,
89	although the sample size was small, ensitedvir treatment led to a reduction in the SARS-CoV-2
90	viral titer and viral RNA versus placebo with an acceptable safety profile ²⁰ . Herein, we present

Page 6 of 37

- 91 the antiviral and clinical efficacy and safety of ensitelvir derived from the phase 2b part of this
 92 phase 2/3 study.
- 93
- 94 **Results**

95 **Patient disposition**

- 96 This phase 2b, dose-finding part of the study (Japan Registry of Clinical Trials identifier:
- 97 jRCT2031210350) was conducted from January 2 to February 9, 2022, at 87 institutions in Japan
- and South Korea (Supplementary Table 1). Of the 437 patients who provided informed consent,
- 99 9 were excluded prior to randomization due to screening failure. Among the 428 patients in total,
- 100 142, 143, and 143 were randomized to receive ensitrelvir 125 mg (375 mg on day 1), ensitrelvir
- 101 250 mg (750 mg on day 1), or placebo, respectively, until day 5; 140, 140, and 141 patients,
- 102 respectively, were included in the safety analysis population. A total of 134, 136, and 139
- 103 patients in the ensitedvir 125 mg, ensitedvir 250 mg, and placebo groups, respectively,
- 104 completed the study. After the exclusion of patients with undetectable SARS-CoV-2 titer at
- 105 baseline or those who provided incomplete informed consent (ensitedvir 125 mg, 28; ensitedvir
- 106 250 mg, 27; and placebo, 32; some patients were excluded from the analysis populations due to
- 107 more than one reason), 341 patients (ensitedvir 125 mg, 114; ensitedvir 250 mg, 116; and
- 108 placebo, 111) were included in the intention-to-treat (ITT) population (Fig. 1). All analyses were
- 109 performed in the planned treatment groups. The ITT population was used for all efficacy
- analyses, and the safety analysis population was used for all safety analyses.

111 Demographics and clinical characteristics

112 The baseline demographics and clinical characteristics of the ITT population are summarized in

113 Table 1. No notable difference was observed in the baseline characteristics across the treatment

Page 7 of 37

114	groups; the	mean age was	s 35.6, 35.3, and	1 37.3 years, and	1 (0.9%), 2 (1.7%),	, and 1 (0.9%)
-----	-------------	--------------	-------------------	-------------------	---------------------	----------------

- 115 patients were aged >65 years in the ensitedvir 125 mg, ensitedvir 250 mg, and placebo groups,
- respectively. A total of 61 (53.5%), 66 (56.9%), and 72 (64.9%) patients in the ensitedvir
- 117 125 mg, ensitrelvir 250 mg, and placebo groups, respectively, were male. Nearly half (ensitrelvir
- 118 125 mg, 55 [48.2%]; ensitedivir 250 mg, 53 [45.7%]; and placebo, 54 [48.6%]) of the patients
- 119 were randomized within 72 hours of COVID-19 symptom onset, and >80% had received at least
- 120 1 dose of mRNA SARS-CoV-2 vaccine (ensitrelvir 125 mg, 97 [85.1%]; ensitrelvir 250 mg,
- 121 97 [83.6%]; and placebo, 97 [87.4%]). Among the predefined 12 COVID-19 symptoms
- 122 (Supplementary Table 2), sore throat (ensitedvir 125 mg, 65 [57.0%]; ensitedvir 250 mg,
- 123 63 [54.3%]; and placebo, 54 [48.6%]) and cough (ensitedvir 125 mg, 48 [42.1%]; ensitedvir
- 124 250 mg, 46 [39.7%]; and placebo, 49 [44.1%]) were most frequently observed in all treatment
- 125 groups.

126 **Treatment compliance**

- 127 The treatment compliance rate in the safety population was high across the treatment groups
- 128 (mean value: ensitrelvir 125 mg, 97.9%; ensitrelvir 250 mg, 99.3%; and placebo, 99.3%).

129 Co-primary efficacy endpoint: SARS-CoV-2 viral titer

- 130 The mean SARS-CoV-2 viral titer, measured as $\log_{10} 50\%$ tissue-culture infectious dose
- 131 ([TCID₅₀]/mL), was comparable across groups at baseline (2.5–2.8 log₁₀ TCID₅₀/mL). In all
- 132 treatment groups, the SARS-CoV-2 viral titer decreased with time for up to day 4 (after the third
- 133 drug administration) and remained stable at the levels of lower limit of detection
- 134 (1.1 log₁₀ TCID₅₀/mL) until day 21 (Fig. 2a,b). The change from baseline in the SARS-CoV-2
- 135 viral titer (log₁₀ TCID₅₀/mL) on day 4, assessed using analysis of covariance (ANCOVA), was
- 136 significantly greater with ensitrelvir 125 mg and 250 mg (least-square [LS] mean [standard error

Page 8 of 37

137	(SE)], -1.49 [0.04];	difference from	placebo, -0.41 [959	% confidence	interval (CI), -0.51 t	.o -0.31];
-----	----------------------	-----------------	---------------------	--------------	------------------------	------------

138 *P*<0.0001) versus placebo (LS mean [SE], -1.08 [0.04]). The change from baseline in the

139 SARS-CoV-2 viral titer on day 4 was significantly greater with ensitrelvir 125 mg and 250 mg

- 140 versus placebo irrespective of COVID-19 vaccination history or time from COVID-19 onset to
- 141 randomization (Supplementary Table 3).

142 **Co-primary efficacy endpoint: Total scores for 12 COVID-19 symptoms**

- 143 The mean total score of the predefined 12 COVID-19 symptoms showed a decreasing trend with
- 144 time after treatment initiation in all groups (Extended Data Fig. 1). There was no significant
- 145 difference in the time-weighted average change from baseline up to 120 hours in the total score
- 146 of the 12 COVID-19 symptoms between the ensitrelvir 125 mg or 250 mg group and the placebo
- 147 group (Table 2).

148 SARS-CoV-2 viral RNA level

- 149 The SARS-CoV-2 RNA level decreased with time in all groups (Fig. 2c,d). The change from
- 150 baseline in SARS-CoV-2 RNA level (log₁₀ copies/mL) on day 4, assessed using ANCOVA, was
- significantly greater with ensitedvir 125 mg (LS mean [SE], -2.58 [0.11]; difference from
- 152 placebo, -1.30 [95% CI, -1.57 to -1.03]; *P*<0.0001) and 250 mg (LS mean [SE], -2.49 [0.11];
- 153 difference from placebo, -1.21 [95% CI, -1.48 to -0.94]; *P*<0.0001) versus placebo (LS mean
- 154 [SE], -1.28 [0.11]). Similarly, the change from baseline in SARS-CoV-2 RNA level was
- significantly greater in the ensitedvir groups versus the placebo group on days 2, 6, and 9.

156 Time to first negative SARS-CoV-2 viral titer

- 157 The time to first negative SARS-CoV-2 viral titer (infectious viral clearance) was significantly
- shorter with ensited vir 125 mg (51.3 hours; difference of median time from placebo, -40.6 hours;

Page 9 of 37

- 159 *P*<0.0001) and 250 mg (62.1 hours; difference of median time from placebo, -29.8 hours;
- 160 *P*<0.0001) versus placebo (91.9 hours) (Fig. 3).

161 **Proportion of patients with a positive SARS-CoV-2 viral titer**

- 162 The proportion of patients with a positive SARS-CoV-2 viral titer decreased with time in all
- treatment groups; on day 4, it was significantly lower with ensitedvir 125 mg (1.9%, P<0.0001)
- and 250 mg (5.4%, P < 0.0001) versus placebo (50.0%), with a reduction of approximately 90%.
- 165 Similarly, the proportion of patients with a positive SARS-CoV-2 viral titer was significantly
- 166 lower with ensitedvir 125 mg and 250 mg versus placebo on day 6 (Extended Data Fig. 2).

167 Subtotal scores for the 12 COVID-19 symptoms

168 The mean changes from baseline in the subtotal scores of the 12 COVID-19 symptoms are

169 depicted in Extended Data Fig. 3. In addition to the preplanned subtotal scores (acute symptoms,

170 main clinical symptoms, respiratory symptoms, systemic symptoms, and digestive symptoms), a

171 composite subtotal score of respiratory symptoms and feverishness was evaluated as a post hoc

- analysis. The time-weighted average change from baseline up to 120 hours was significantly
- 173 greater with ensitrelvir versus placebo in the subtotal scores for acute symptoms (250 mg group,

174 *P*=0.0070), main clinical symptoms (250 mg group, *P*=0.0149), respiratory symptoms (125 mg

- and 250 mg groups, *P*=0.0153 and 0.0033, respectively), and the composite of respiratory
- symptoms and feverishness (125 mg and 250 mg groups, *P*=0.0164 and 0.0039, respectively). In

177 contrast, no significant difference was observed between the ensitrelvir and placebo groups in the

time-weighted average change for systemic symptoms and digestive symptoms (Supplementary

- 179 Table 4). The anosmia and dysgeusia scores generally showed a transient increase from baseline,
- 180 suggesting a delayed onset of these symptoms in patients with COVID-19. The change from

Page 10 of 37

- 181 baseline in the anosmia and dysgeusia scores was lower with ensitrelyir 125 mg and 250 mg
- 182 versus placebo (Extended Data Fig. 4).
- 183 No significant difference was observed in the time to first improvement of COVID-19
- 184 symptoms (median [95% CI] hours: 28.0 [21.5 to 36.6], 27.8 [24.6 to 40.0], and 36.6 [28.0 to
- 185 40.8] for ensitelvir 125 mg, ensitelvir 250 mg, and placebo, respectively).
- 186 COVID-19 exacerbation
- 187 After treatment initiation, 1 vaccinated patient in the ensited via 250 mg group was rated as ≥ 3
- 188 (corresponding to hospitalization or death) by the investigator on an 8-point ordinal scale for
- 189 disease exacerbation. None of the patients in the ensitrelvir 125 mg and placebo groups recorded
- 190 \geq 3 on the disease exacerbation scale.
- 191 Safety
- 192 Overall, 48 (34.3%), 60 (42.9%), and 44 (31.2%) patients in the ensitedvir 125 mg, ensitedvir
- 193 250 mg, and placebo groups, respectively, reported treatment-emergent adverse events (TEAEs),
- 194 most of which were mild in severity. Treatment-related adverse events (AEs) were observed in
- 195 19 (13.6%), 31 (22.1%), and 7 (5.0%) patients in the ensitedvir 125 mg, ensitedvir 250 mg, and
- 196 placebo groups, respectively, a majority of which were resolved without sequelae. A decrease in
- 197 high-density lipoprotein (HDL) levels was most frequently reported as a TEAE across groups
- 198 (ensitelvir 125 mg, 31 [22.1%] patients; ensitelvir 250 mg, 40 [28.6%] patients; and placebo, 5
- 199 [3.5%] patients) and was the most common treatment-related AE in both ensittelvir groups
- 200 (125 mg, 13 [9.3%] patients; 250 mg, 22 [15.7%] patients). No TEAEs leading to death were
- 201 reported during the study (Table 3).
- 202 Two patients in the placebo group had serious TEAEs (thoracic vertebral fracture
 203 [recovered without sequelae] and facial paralysis [recovering]), both of which were determined

Page 11 of 37

204	as not treatment related. Another 2 patients in the ensitrelvir 125 mg group discontinued the
205	treatment due to TEAEs. All 3 TEAEs leading to treatment discontinuation (mild eczema on day
206	2 in 1 patient and moderate nausea and mild headache on day 2 in 1 patient) were judged as
207	treatment related by the investigator, and both patients recovered without sequelae after drug
208	discontinuation.
209	A dose-dependent, transient change in the HDL cholesterol, triglyceride, total bilirubin,
210	and iron levels was observed on day 6 in the ensitrelvir groups (Extended Data Fig. 5). These
211	changes were asymptomatic and resolved without additional treatment.
212	No notable difference was observed with ensitrelvir treatment versus placebo in the
213	haptoglobin, reticulocyte, or low-density lipoprotein levels, and no laboratory or clinical signs of
214	hemolysis were observed. None of the patients showed serum bilirubin increase occurring
215	concurrently with liver enzyme elevation.
216	
217	Discussion
218	This phase 2b part of a randomized, double-blind, placebo-controlled, phase 2/3 trial of
219	ensitrelvir in patients with mild-to-moderate COVID-19 was conducted in early 2022 during the
220	SARS-CoV-2 Omicron epidemic. Based on the results of the phase 2a part conducted during the
221	SARS-CoV-2 Delta epidemic ²⁰ , which showed a statistically significant reduction in the
222	SARS-CoV-2 viral titer and an improving trend in the total score of the 12 COVID-19 symptoms
223	after ensitrelvir treatment, we used these outcomes as the co-primary endpoints. On day 4,
224	ensitrelvir treatment significantly reduced the SARS-CoV-2 viral titer versus placebo. There was
225	no significant difference from placebo in the time-weighted average change from baseline up to
226	120 hours in the total score of the 12 COVID-19 symptoms. Of note, because of the difference in

Page 12 of 37

227	the predominant SARS-CoV-2 variants, virologic characteristics and clinical disease course
228	observed in this phase 2b part may not be consistent with those observed in the phase 2a part or
229	previous anti-COVID-19 clinical trials and may affect the interpretation of the virologic and
230	clinical efficacy of ensitrelvir.
231	In the current phase 2b part, virologic efficacy was assessed using the change in
232	SARS-CoV-2 viral titer from baseline to day 4 (co-primary endpoint) and SARS-CoV-2 RNA
233	(endpoint commonly used in clinical studies for anti-COVID-19 treatments ^{14,16,21}). The rapid and
234	significant reduction in the SARS-CoV-2 viral titer and viral RNA following ensitrelvir
235	treatment is consistent with the findings of the previous phase 2a part ²⁰ , but the level of viral titer
236	reduction from baseline to day 4 was lower in the current phase 2b part (-1.49 $\log_{10} \text{TCID}_{50}/\text{mL}$)
237	than in the phase 2a part (-2.81 \log_{10} TCID ₅₀ /mL with ensited vir 250 mg) ²⁰ . These differences in
238	findings may be attributed to the lower baseline titer recorded in the phase 2b part than in the
239	phase 2a part (2.5–2.8 versus 3.3–3.7 log_{10} TCID ₅₀ /mL), as well as other unidentified differences
240	in viral characteristics. Indeed, previous research findings indicate different characteristics
241	between the Omicron and Delta variants in the infectivity or peak viral titer measured in Vero-E6
242	cells ²² and peak viral load and viral clearance ²³ , despite the consistent antiviral efficacy of
243	ensitrelvir against the Omicron variant shown in preclinical research ¹⁷⁻¹⁹ . The difference from
244	placebo in the reduction in SARS-CoV-2 RNA observed from baseline to day 4 in the current
245	phase 2b part (-1.30 and -1.21 log ₁₀ copies/mL for ensitrelvir 125 and 250 mg, respectively)
246	appeared greater than that observed with molnupiravir 800 mg (day 5, -0.547 \log_{10} copies/mL) ²¹ ,
247	nirmatrelvir 300 mg in combination with ritonavir 100 mg (day 5, -0.868 \log_{10} copies/mL) ¹⁴ , or
248	casirivimab/imdevimab 2400 mg (day 7, -0.86 \log_{10} copies/mL) ¹⁶ . The majority of patients
249	enrolled in the current phase 2b part were vaccinated, whereas previous anti-COVID-19

Page 13 of 37

250	treatments were evaluated in unvaccinated patients at risk of severe disease ^{13,14} . Although no
251	direct comparison with previous clinical trials is feasible due to differences in study settings, our
252	results support the promising efficacy of ensitrelvir in real-world clinical settings. Moreover, no
253	notable viral rebound (increase in viral titer or RNA) was observed on day 14 or 21 of ensitrelvir
254	treatment in contrast to the findings observed with nirmatrelvir treatment
255	(https://www.fda.gov/media/155194/download). The absence of viral rebound may be attributed
256	to a longer half-life of ensitrelvir (51.4 hours; R. Shimizu et al., unpublished data) versus
257	nirmatrelvir 250 mg in combination with ritonavir 100 mg (approximately 6.5 hours) ²⁴ , which
258	should be further assessed in large-scale, confirmatory trials.
259	Clinical efficacy, such as a symptom relief, is a pivotal part of COVID-19 clinical trials
260	because patients present with diverse symptoms ²⁵ and clinical symptoms may differ depending
261	on the epidemic variants. Although the decreasing trend in the total 12 COVID-19 symptom
262	scores is consistent with the findings from the phase 2a part ²⁰ , the results of the current phase 2b
263	part indicate differences in the symptom characteristics between the Omicron and Delta variant
264	infections. Among the 12 symptoms assessed, respiratory symptoms and feverishness were
265	recorded in many patients enrolled in the phase 2b part, whereas systemic and digestive
266	symptoms were relatively less observed at baseline. These findings can be explained by an
267	epidemiology report in Japan, where the most commonly reported COVID-19 symptoms in
268	patients infected with the Omicron variant were respiratory symptoms, such as cough (46.0%),
269	sore throat (33.8%), runny nose (18.0%), and fever (30.9%) (https://www.niid.go.jp/niid/ja/2019-
270	ncov/2484-idsc/10969-covid19-72.html; website in Japanese). The absence of significant
271	intergroup difference in the total score of the 12 COVID-19 symptoms can be attributed to the
272	low baseline subtotal scores recorded for some patients (e.g., digestive symptoms) in the current

Page 14 of 37

273	phase 2b part. Interestingly, ensittelvir treatment improved respiratory symptoms or a composite
274	outcome of respiratory symptoms and feverishness versus placebo, which suggests the potential
275	clinical benefits of this antiviral in patients infected with the Omicron variant.
276	The current phase 2b part of the study found no clear dose response, which is consistent
277	with the findings of the phase 2a part ²⁰ . Pharmacokinetic data for 5-day ensitedvir 125 mg
278	treatment (375 mg on day 1) derived from the phase 1 study of ensitrelvir (maximum plasma
279	concentration, 30.4 μ g/mL; area under the curve, 598.3 μ g·hr/mL) suggest that this regimen is
280	sufficient to achieve a reduction in SARS-CoV-2 in humans (R. Shimizu et al., unpublished
281	data). Ensitrelvir 125 mg (375 mg on day 1) is thus considered the optimal dose for achieving an
282	antiviral effect while minimizing drug exposure.
283	Infection with the Omicron variant causes less severe disease than infection with the
284	Delta variant ²⁶⁻²⁸ , which may be attributed to altered infectivity and attenuated lung disease with
285	the Omicron variant observed in rodent models ²⁹ or immunity acquired via previous viral
286	exposure through vaccination and/or past infections ^{27,28} . In the current phase 2b part, >95% of
287	patients receiving placebo showed symptom improvement by day 5, and the median time to first
288	improvement of the 12 COVID-19 symptoms (27.8–36.6 hours) was shorter than that observed
289	in the previous phase 2a part (36.7–55.2 hours), which may reflect less disease severity of
290	infection with the Omicron variant. New clinical endpoints that can assess the clinical symptoms
291	of COVID-19 are warranted.
292	In addition to treatment options for patients at risk of severe disease, effective antivirals
293	that can rapidly reduce SARS-CoV-2 are warranted because patients with asymptomatic or
294	mild-to-moderate COVID-19 may shed infectious viruses for up to 10 days and may be a source
295	for viral transmission ³⁰ . Early treatment initiation for mild-to-moderate COVID-19 is necessary

Page 15 of 37

296	in view of the disease characteristics and to gain maximum benefits from pharmacological
297	therapies

- 298 (https://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_drug_220218.pdf; website
- in Japanese). Moreover, long-term complications after COVID-19, such as loss of taste and/or
- 300 smell, fatigue, headache, attention disorder, hair loss, and dyspnea, can occur in the relatively
- 301 healthy population (e.g., young adults or patients with mild disease) and contribute toward
- 302 persistent and significant health issues^{31,32}. Although the exact mechanism of the onset of
- 303 long-term COVID-19 complications is unknown, rapid SARS-CoV-2 reduction with ensitrelvir
- 304 treatment may be effective in suppressing these complications, which should be assessed in an

305 optional, exploratory period (days 28 to 337) of the current phase 2/3 study.

Similar to the previous phase 1 study (R. Shimizu et al., unpublished data) and phase 2a part of the current study²⁰, a transient change in the HDL cholesterol and triglyceride levels was observed in patients treated with ensitrelvir. In addition, total bilirubin and iron levels transiently increased with ensitrelvir treatment. The underlying causes of these laboratory findings and their potential relationship with ensitrelvir treatment warrant further investigation.

This study has some limitations. The number of elderly patients (aged ≥ 65 years) was limited; thus, data analysis for this population was not feasible. As the risk of severe COVID-19 increases with age³³, the safety and efficacy of ensitrelvir in a wide range of patients with COVID-19 should be further assessed in the phase 3, multinational, randomized, placebocontrolled study, SCORPIO-HR (ClinicalTrials.gov identifier: NCT05305547). Moreover, as new variants may arise in the future, continuous monitoring and assessment of ensitrelvir activity against new VOCs would be required. In addition to the preclinical antiviral activity of

Page 16 of 37

318	ensitrelvir against a variety of SARS-CoV-2 variants ¹⁷ , evidence derived in clinical trial settings
319	is awaited.
320	In conclusion, 5-day, once daily, oral ensitrelvir treatment demonstrated rapid and
321	favorable antiviral efficacy with an acceptable safety profile in patients with mild-to-moderate
322	COVID-19, a majority of whom had been vaccinated. Ensittelvir treatment improved respiratory
323	symptoms and feverishness, which were common COVID-19 symptoms during the Omicron
324	variant epidemic. The results support further clinical development of ensitrelvir for mild-to-
325	moderate COVID-19.
326	
327	Methods
328	Study design
329	Patients with mild-to-moderate COVID-19 were randomized (1:1:1) to orally receive ensitrelyir
330	fumaric acid (375 mg on day 1, followed by 125 mg on days 2 through 5, or 750 mg on day 1,
331	followed by 250 mg on days 2 through 5) or matching placebo once daily without dose
332	modification and followed up until day 28.
333	This study was conducted in accordance with the principles of the Declaration of
334	Helsinki, Good Clinical Practice guidelines, and other applicable laws and regulations. The study
335	was reviewed and approved by the institutional review boards of all participating institutions
336	listed in Supplementary Table 1. All patients or their legally acceptable representatives provided
337	written informed consent.
338	Patients
339	Patients aged 12 to 69 years who tested positive for SARS-CoV-2 (assessed by SARS-CoV-2
340	antigen or nucleic acid detection testing) within 120 hours prior to randomization were eligible

Page 17 of 37

341	for study enrollment. To avoid excess drug exposure, patients aged <20 years should have
342	recorded a body weight of \geq 40 kg at enrollment. Patients should have at least one moderate or
343	severe symptom or worsening of an existing symptom among the 12 COVID-19 symptoms
344	(stuffy or runny nose, sore throat, shortness of breath, cough, low energy or tiredness, muscle or
345	body aches, headache, chills or shivering, feeling hot or feverish, nausea, vomiting, or diarrhea;
346	Supplementary Table 2) based on the US Food and Drug Administration (US FDA) guidance
347	(https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-covid-
348	19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drugs) and a
349	symptom duration of \leq 120 hours. In Japan, patients were eligible for enrollment irrespective of
350	treatment settings (inpatient, outpatient, recuperation at home, or recuperation at designated
351	hotels) because some of them required hospitalization or recuperation for the purpose of isolation
352	or clinical trial participation, regardless of disease severity, at the time of this research.
353	The key exclusion criteria included the following: an awake oxygen saturation of $\leq 93\%$
354	(room air); oxygen administration; likely worsening of COVID-19 within 48 hours from
355	randomization in the opinion of the investigator; suspected active and systemic infections
356	requiring treatment (except for COVID-19); current or chronic history of moderate or severe
357	liver disease, known hepatic or biliary abnormalities (except for Gilbert's syndrome or
358	asymptomatic gallstones), or moderate-to-severe kidney disease; pregnant, possibly pregnant, or
359	breastfeeding women; and blood donation (\geq 400 mL within 12 weeks or \geq 200 mL within
360	4 weeks prior to enrollment). Patients who had used drugs for SARS-CoV-2 infection within
361	7 days prior to randomization or a strong cytochrome P450, family 3, subfamily A (CYP3A)
362	inhibitor or inducer or St. John's wort products within 14 days prior to randomization were also
363	excluded.

Page 18 of 37

364 Randomization and blinding

365 Randomization of patients was performed through an interactive response technology system 366 using time from the onset of COVID-19 to randomization (<72 hours/ \geq 72 hours) and the first 367 COVID-19 vaccination (Yes/No) as stratification factors. All patients and study staff were 368 blinded to the treatment, except for designated persons at the sponsor and contract research 369 organization in charge of statistical analyses. When all patients completed the day 6 assessment, 370 the study sponsor was unblinded to intervention allocation to allow for an early-stage evaluation 371 of the efficacy and safety data. Investigators, patients, and other study staff remained blinded 372 until the completion of the 28-day follow-up period. Emergency unblinding per the investigator's 373 request was allowed only in the event of AEs to determine appropriate therapy for the patient. 374 Treatment 375 Patients received allocated study drugs orally (ensited vir fumaric acid 125 mg, 250 mg, or 376 placebo tablets), which were indistinguishable in appearance, labeling, and packaging. Prohibited 377 concomitant medications (study initiation to day 28 or study discontinuation) included drugs for 378 the treatment of SARS-CoV-2 infection; antiviral, antibacterial, or antifungal drugs (except for 379 topical use); antipyretic analgesics other than acetaminophen; antitussives and expectorants; 380 combination cold remedy; and CYP3A substrates. Drugs prohibited for use from study initiation 381 to 10 days after the last study drug administration (or study discontinuation) included strong 382 CYP3A inhibitors or inducers, strong P-glycoprotein or breast cancer resistance protein 383 inhibitors, and other transporter substrates. Treatment was discontinued when liver function 384 abnormalities, pregnancy, COVID-19 exacerbation, or serious or intolerable AEs were observed. 385 **Outcomes and assessments**

Page 19 of 37

386	The primary virologic outcome was change from baseline (day 1, before drug administration) in
387	the SARS-CoV-2 viral titer on day 4 of treatment. The primary clinical outcome was
388	time-weighted average change from baseline up to 120 hours in the total score of COVID-19
389	symptoms. The co-primary endpoint was constructed by the primary virologic and clinical
390	outcomes. The secondary outcomes included the SARS-CoV-2 viral titer and viral RNA level
391	(absolute values and change from baseline) up to day 21, time to first negative SARS-CoV-2
392	viral titer (infectious viral clearance), proportion of patients with positive viral titers, subtotal
393	scores of the 12 COVID-19 symptoms (acute symptoms, main clinical symptoms, respiratory
394	symptoms, systemic symptoms, and digestive symptoms; Supplementary Table 2), time to first
395	improvement of COVID-19 symptoms (Supplementary Table 2), and COVID-19 exacerbations
396	assessed by the investigator. Additionally, post hoc analyses were performed to assess a
397	composite subtotal score (respiratory symptoms and feverishness) for the 12 COVID-19
398	symptoms.

399 Nasopharyngeal swabs were collected from the patients on days 1 (before drug 400 administration), 2 to 6 (days 3 and 5 as optional), 9, 14, and 21 (or study discontinuation), and 401 the SARS-CoV-2 viral titers and RNA levels were centrally measured at Shionogi 402 TechnoAdvance Research (Osaka, Japan) and Viroclinics (Rotterdam, Netherlands), 403 respectively. For the assessment of COVID-19 symptoms, patients rated each symptom on a 404 4-point or 3-point scale (Supplementary Table 2) and recorded the scores in a diary twice daily 405 (morning and evening) until day 9 and once daily (evening) from days 10 to 21. Additionally, 406 patients' COVID-19 exacerbation was assessed by the investigator using an 8-point ordinal scale 407 (0=Asymptomatic; 1=Symptomatic, no limitation of activities; 2=Symptomatic, limitation of 408 activities; 3=Hospitalized, no oxygen therapy; 4=Hospitalized, with oxygen therapy [<5 L/min];

Page 20 of 37

409	5=Hospitalized, with oxygen therapy [\geq 5 L/min]; 6=Hospitalized, with ventilation; 7=Death) on
410	day 1 (before drug administration) and days 2, 4, 6, 9, 14, 21, and 28 (or study discontinuation).
411	Safety was assessed by the occurrence of TEAEs, that is, any AEs reported after the
412	initiation of study intervention. All AEs were coded and classified using Medical Dictionary for
413	Regulatory Activities version 24.0. Laboratory tests, vital sign measurements, and
414	electrocardiography were additionally performed throughout the study period. All safety data
415	were evaluated by an independent data and safety monitoring board. Pregnancy tests were
416	performed for women with childbearing potential on days 1 (before drug administration) and 28
417	(or study discontinuation). Additional pregnancy tests at the investigator's discretion were
418	permitted.
419	Statistical analyses
420	Based on the interim evaluation of the phase 2a part of this study (Shionogi & Co., Ltd.,
421	unpublished data), the difference in time-weighted average change in the total score of
422	COVID-19 symptoms from baseline up to 120 hours between the ensitrelvir and placebo groups
423	was assumed to be -1, with a standard deviation (SD) of 2.6. A total of 108 patients per group
424	(324 in total) were required to detect this difference with 80% power using a two-sample t-test at
425	a one-sided significance level of 0.025. The same sample size was required to detect the
426	intergroup difference in change from baseline in the SARS-CoV-2 viral titer on day 4 with
427	99.9% power using a two-sample t-test at a one-sided significance level of 0.025, assuming a
428	difference between the ensittelvir and placebo groups of -0.5 $\log_{10} \text{TCID}_{50}/\text{mL}$ and an SD of
429	$0.7 \log_{10} TCID_{50}/mL$. Considering a dropout rate of 25% (proportion of patients with a negative
430	SARS-CoV-2 viral titer at baseline), the final sample size was set at 145 patients per group (435
431	in total).

Page 21 of 37

432	All randomized patients with a positive SARS-CoV-2 viral titer ($\geq 1.1 \log_{10} \text{TCID}_{50}/\text{mL}$)
433	at baseline were included in the ITT population. All randomized patients who received at least
434	one dose of the study drug were included in the safety analysis population.

435 A prespecified statistical hypothesis was set, wherein both virologic and clinical 436 efficacy are confirmed if differences in the co-primary endpoints of virologic and clinical 437 outcomes between the ensited vir (125 mg or 250 mg) and placebo groups are statistically 438 significant at a one-sided significance level of 0.025. To control the type I error for multiplicity 439 of testing that occurred in pairwise comparisons between each of the ensited vir dose groups and 440 the placebo group, a fixed sequence procedure was applied to the primary virologic and clinical 441 outcomes, where the statistical tests were performed in the order of ensited vir 125 mg versus 442 placebo and ensitrelvir 250 mg versus placebo. Other statistical tests were performed at a 443 two-sided significance level of 0.05.

444 An ANCOVA model was constructed for the primary analysis of the primary endpoints 445 for pairwise comparison of each efficacy outcome between each of the ensittelvir groups and the 446 placebo group using baseline values, time from COVID-19 onset to randomization (<72 or 447 \geq 72 hours), and COVID-19 vaccination history (Yes or No) as covariates. LS mean, difference 448 from placebo, and 95% CI were calculated based on the ANCOVA model. Time-weighted 449 average change from baseline up to 120 hours in the total score of the 12 COVID-19 symptoms 450 was calculated by dividing the area under the curve up to 120 hours for change from baseline in 451 the total score of the 12 COVID-19 symptoms by hours from the start of first drug 452 administration. A Kaplan-Meier curve was plotted for the analyses of time to first negative 453 SARS-CoV-2 viral titer and time to first improvement of COVID-19 symptoms, and the median 454 time was compared between each of the ensitted rough and the placebo group using a

Page 22 of 37

455	log-rank test stratified by time from COVID-19 onset to randomization and COVID-19
456	vaccination history. The proportion of patients with a positive SARS-CoV-2 viral titer was
457	compared between each of the ensitrelvir groups and the placebo group using the
458	Mantel-Haenszel test, stratified by time from COVID-19 onset to randomization and
459	SARS-CoV-2 vaccination history.
460	No imputation was performed for missing data. All analyses were performed using SAS
461	version 9.4 (SAS Institute, Inc., Cary, NC, USA).
462	
463	Data availability
464	Shionogi & Co., Ltd. is committed to disclosing the synopses and results of its clinical trials and
465	sharing the clinical trial data with researchers on reasonable request. For further details, please
466	refer to the websites of Shionogi & Co., Ltd.
467	(https://www.shionogi.com/shionogi/global/en/company/policies/shionogi-group-clinical-trial-
468	data-transparency-policy.html) and Vivli (https://vivli.org/).
469	
470	Acknowledgments
471	The authors and research team thank all the patients involved in this study and Masahiro
472	Kinoshita and Satoshi Kojima (Shionogi & Co., Ltd.) for preparing technical support documents
473	and an earlier version of the manuscript draft. Support for study monitoring and data
474	management was provided by EPS Corporation and funded by Shionogi & Co., Ltd. Medical
475	writing and editorial assistance was provided by Mami Hirano, MS, of Cactus Life Sciences (part
476	of Cactus Communications) and funded by Shionogi & Co., Ltd. All authors retained full
477	ownership of the manuscript content and approved the final draft for submission.

Page 23 of 37

478	This study was sponsored by Shionogi & Co., Ltd., and financially supported by the
479	Organization of the Ministry of Health, Labour and Welfare. Employees of Shionogi & Co., Ltd.,
480	participated in and approved the design and conduct of the study; wrote the protocol; and were
481	involved in the collection, management, analysis, and interpretation of data. Institutional authors
482	reviewed and approved the protocol and collected and interpreted the data.

483 H. Mukae has received funding relevant to the submitted work from Shionogi and grants 484 from Taisho Pharma; lecture fees from Pfizer, MSD, Shionogi, and Taisho Pharma; and advisory 485 fees from Pfizer, MSD, and Shionogi outside the submitted work. H. Yotsuyanagi has received 486 consulting fees from Shionogi, lecture fees from Shionogi and ViiV Healthcare, and travel 487 support from Shionogi outside the submitted work. He serves as an advisory board member of 488 Shionogi and President of the Japanese Society of Infectious Diseases. Y. Doi has received 489 grants from Shionogi and Entasis; consulting fees from Shionogi, Meiji Seika Pharma, Gilead 490 Sciences, GSK, MSD, Chugai, and bioMerieux; and lecture fees from MSD, AstraZeneca, 491 Shionogi, and Teijin Healthcare outside the submitted work and serves as an advisory board 492 member of FujiFilm. H. Sakaguchi, T. Sonoyama, G. Ichihashi, T. Sanaki, K. Baba, Y. Tsuge, 493 and T. Uehara are full-time employees of Shionogi & Co., Ltd., and may have stocks or stock 494 options. N. Ohmagari declares no conflict of interest.

495 Author contributions: H. Mukae, H. Yotsuyanagi, N. Ohmagari, Y. Doi, T. Sonoyama, Y.

496 Tsuge, and T. Uehara conceived and designed the experiments and wrote the paper. H.

497 Sakaguchi conceived and designed the experiments, analyzed the data, contributed

498 materials/analysis tools, and wrote the paper. G. Ichihashi conceived and designed the

499 experiments and contributed materials/analysis tools. T. Sanaki conceived and designed the

500 experiments, performed the experiments, analyzed the data, contributed materials/analysis tools,

Page 24 of 37

- 501 and wrote the paper. K. Baba performed the experiments, analyzed the data, contributed
- 502 materials/analysis tools, and wrote the paper.

503

Page 25 of 37

References 504 505 Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. 1 506 J. Med. 384, 403–416 (2021). 507 2 Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. 508 Engl. J. Med. 383, 2603–2615 (2020). 509 3 Voysey, M. et al. Single-dose administration and the influence of the timing of the 510 booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) 511 vaccine: a pooled analysis of four randomised trials. *Lancet* 397, 881–891 (2021). 512 4 Heath, P. T. et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N. Engl. J. 513 Med. 385, 1172–1183 (2021). 514 5 Levin, E. G. et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine 515 over 6 months. N. Engl. J. Med. 385, e84 (2021). 516 6 Bergwerk, M. et al. Covid-19 breakthrough infections in vaccinated health care workers. 517 N. Engl. J. Med. 385, 1474–1484 (2021). 518 7 Lambrou, A. S. et al. Genomic surveillance for SARS-CoV-2 variants: predominance of 519 the Delta (B.1.617.2) and Omicron (B.1.1.529) variants - United States, June 2021-520 January 2022. MMWR Morb. Mortal. Wkly. Rep. 71, 206–211 (2022). 521 8 Ao, D. et al. SARS-CoV-2 Omicron variant: immune escape and vaccine development. 522 MedComm (2020). 3, e126 (2022). 523 9 Kumar, S. et al. Omicron and Delta variant of SARS-CoV-2: a comparative 524 computational study of spike protein. J. Med. Virol. 94, 1641–1649 (2022). 525 10 Wolter, N. et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron 526 variant in South Africa: a data linkage study. Lancet 399, 437-446 (2022).

Page 26 of 37

527	11	Auvigne, V	. et al. Severe	hospital events	following symp	ptomatic infection	with Sars-
-----	----	------------	-----------------	-----------------	----------------	--------------------	------------

- 528 CoV-2 Omicron and Delta variants in France, December 2021 January 2022: a
- 529 retrospective, population-based, matched cohort study. *eClinicalMedicine* doi:
- 530 10.1016/j.eclinm.2022.101455 Error! Hyperlink reference not valid.(2022).
- 531 12 Nyberg, T. et al. Comparative analysis of the risks of hospitalisation and death associated
- 532 with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a
- 533 cohort study. *Lancet* 399, 1303–1312 (2022).
- 53413Jayk Bernal, A. et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized
- 535 patients. N. Engl. J. Med. 386, 509–520 (2022).
- Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. *N. Engl. J. Med.* 386, 1397–1408 (2022).
- 538 15 Gupta, A. et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody
 539 sotrovimab. *N. Engl. J. Med.* 385, 1941–1950 (2021).
- 540 16 Weinreich, D. M. et al. REGEN-COV antibody combination and outcomes in outpatients
- 541 with Covid-19. *N. Engl. J. Med.* 385, e81 (2021).
- 542 17 Unoh, Y. et al. Discovery of S-217622, a non-covalent oral SARS-CoV-2 3CL protease

543 inhibitor clinical candidate for treating COVID-19. J. Med. Chem. doi:

- 544 10.1021/acs.jmedchem.2c00117 (2022).
- 545 18 Uraki, R. et al. Characterization and antiviral susceptibility of SARS-CoV-2
- 546 Omicron/BA.2. *Nature* doi: 10.1038/s41586-022-04856-1 (2022).
- 547 19 Sasaki, M., Tabata, K., Kishimoto, M., Itakura, Y., Kobayashi, H., Ariizumi, T., Uemura,
- 548 K., Toba, S., Kusakabe, S., Maruyama, Y., Iida, S., Nakajima, N., Suzuki, T., Yoshida, S.,
- 549 Nobori, H., Sanaki, T., Kato, T., Shishido, T., Hall, W. W., Orba, Y., Sato, A. & Sawa, H.

Page 27 of 37

550 Oral administration of S-217622, a SARS-CoV-2 main	protease inhibitor, decreases viral
--	-------------------------------------

- 551 load and accelerates recovery from clinical aspects of COVID-19. Preprint at *bioRxiv*
- 552 https://www.biorxiv.org/content/10.1101/2022.02.14.480338v1.full (2022).
- 553 20 Mukae, H., Yotsuyanagi, H., Ohmagari, N., Doi, Y., Imamura, T., Sonoyama, T.,
- 554 Fukuhara, T., Ichihashi, G., Sanaki, T., Baba, K., Takeda, Y., Tsuge, Y. & Uehara, T. A
- randomized phase 2/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease
- 556 inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-
- 557 CoV-2 infection: results of the phase 2a part. Preprint at *medRxiv*
- 558 <u>https://www.medrxiv.org/content/10.1101/2022.05.17.22275027v1</u> (2022).
- 559 21 Fischer, W. A., 2nd et al. A phase 2a clinical trial of molnupiravir in patients with
- 560 COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious
 561 virus. *Sci. Transl. Med.* 14, eabl7430 (2022).
- 562 22 Mautner, L. et al. Replication kinetics and infectivity of SARS-CoV-2 variants of

563 concern in common cell culture models. *Virol. J.* 19, 76 (2022).

- Hay, J. A., Kissler, S. M., Fauver, J. R., Mack, C., Tai, C. G., Samant, R. M., Connelly,
- 565 S., Anderson, D. J., Khullar, G., MacKay, M., Patel, M., Kelly, S., Manhertz, A., Eiter, I.,
- 566 Salgado, D., Baker, T., Howard, B., Dudley, J. T., Mason, C. E., Ho, D. D., Grubaugh, N.
- 567 D. & Grad, Y. H. Viral dynamics and duration of PCR positivity of the SARS-CoV-2
- 568 Omicron variant. Preprint at *medRxiv*
- 569 <u>https://www.medrxiv.org/content/10.1101/2022.01.13.22269257v1</u> (2022).
- 570 24 Singh, R. S. P. et al. Innovative randomized phase I study and dosing regimen selection
- 571 to accelerate and inform pivotal COVID-19 trial of nirmatrelvir. *Clin. Pharmacol. Ther.*
- 572 doi: 10.1002/cpt.2603 (2022).

Page 28 of 37

573	25	Rodebaugh, T. L. et al. Acute symptoms of mild to moderate COVID-19 are highly
574		heterogeneous across individuals and over time. Open Forum Infect. Dis. 8, ofab090
575		(2021).
576	26	Johnson, A. G. et al. COVID-19 incidence and death rates among unvaccinated and fully
577		vaccinated adults with and without booster doses during periods of Delta and Omicron
578		variant emergence - 25 U.S. jurisdictions, April 4-December 25, 2021. MMWR Morb.
579		Mortal. Wkly. Rep. 71, 132–138 (2022).
580	27	Davies, M-A. et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection in the
581		Omicron-driven fourth wave compared with previous waves in the Western Cape
582		Province, South Africa. Trop. Med. Int. Health. doi: 10.1111/tmi.13752 (2022).
583	28	Veneti, L. et al. Reduced risk of hospitalisation among reported COVID-19 cases
584		infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant,
585		Norway, December 2021 to January 2022. Euro. Surveill. 27, 2200077 (2022).
586	29	Halfmann, P. J. et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and
587		hamsters. Nature 603, 687-692 (2022).
588	30	Singanayagam, A. et al. Duration of infectiousness and correlation with RT-PCR cycle
589		threshold values in cases of COVID-19, England, January to May 2020. Euro. Surveill.
590		25, 2001483 (2020).
591	31	Blomberg, B. et al. Long COVID in a prospective cohort of home-isolated patients. Nat.
592		Med. 27, 1607–1613 (2021).
593	32	Lopez-Leon, S. et al. More than 50 long-term effects of COVID-19: a systematic review
594		and meta-analysis. Sci. Rep. 11, 16144 (2021).

Page 29 of 37

- 595 33 Pennington, A. F. et al. Risk of clinical severity by age and race/ethnicity among adults
- 596 hospitalized for COVID-19-United States, March-September 2020. *Open Forum Infect.*
- 597 Dis. 8, ofaa638 (2020).

Page 30 of 37

598 FIGURE LEGENDS

599 Fig. 1: Patient disposition.

- 600 Some patients were excluded from the analysis populations due to more than one reason.
- 601 AE, adverse event; ITT, intention-to-treat.
- 602
- 603 Fig. 2: a, Absolute values and b, change from baseline in SARS-CoV-2 viral titer; c,
- absolute values and d, change from baseline in SARS-CoV-2 RNA level (ITT
- 605 **population**).
- 606 Data are presented as mean \pm SD. **P*<0.05 versus placebo. Dotted lines indicate the lower
- 607 limit of detection for SARS-CoV-2 viral titer (1.1 log₁₀ TCID₅₀/mL) and lower limit of
- 608 quantification for SARS-CoV-2 RNA level (2.08 log₁₀ copies/mL).
- 609 ITT, intention-to-treat; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD,
- 610 standard deviation; TCID₅₀, 50% tissue-culture infectious dose.
- 611
- 612 Fig. 3: Time to first negative SARS-CoV-2 viral titer (viral clearance; ITT population).
- 613 CI, confidence interval; ITT, intention-to-treat; SARS-CoV-2, severe acute respiratory
- 614 syndrome coronavirus 2.

Page 31 of 37

015 Extended data	615	Extended	data
-------------------	-----	----------	------

- 616 Extended Data Fig. 1 a, Mean absolute values and b, mean change from baseline in the
- 617 total score of the 12 COVID-19 symptoms (ITT population).
- 618 COVID-19, coronavirus disease 2019; ITT, intention-to-treat.
- 619
- 620 Extended Data Fig. 2 Proportion of patients with a positive SARS-CoV-2 viral titer
- 621 (ITT population).
- 622 **P*<0.05 versus placebo.
- 623 ITT, intention-to-treat; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

624

- 625 Extended Data Fig. 3 Mean change from baseline in subtotal scores of the 12 COVID-19
- 626 symptoms for a, acute symptoms, b, main clinical symptoms, c, respiratory symptoms,
- 627 d, systemic symptoms, e, digestive symptoms, and f, respiratory symptoms and
- 628 feverishness (ITT population).
- 629 COVID-19, coronavirus disease 2019; ITT, intention-to-treat.
- 630
- 631 Extended Data Fig. 4 Mean change from baseline in anosmia and dysgeusia scores (ITT
- 632 population).
- 633 Avg, average; ITT, intention-to-treat.
- 634
- 635 Extended Data Fig. 5 Levels of a, HDL cholesterol, b, triglycerides, c, total bilirubin,
- 636 and d, iron (safety analysis population).
- 637 Data are presented as mean±SD.
- 638 Avg, average; HDL, high-density lipoprotein; SD, standard deviation.

TABLES

Table 1 Baseline demographics and clinical characteristics (ITT population)

Variables	Ensitrelvir 125 mg	Ensitrelvir 250 mg	Placebo
	(N=114)	(N=116)	(N=111)
Male sex, <i>n</i> (%)	61 (53.5)	66 (56.9)	72 (64.9)
Age, years, mean (SD)	35.6 (13.5)	35.3 (13.1)	37.3 (12.6)
Age, <i>n</i> (%)			
\geq 12 to <18 years	4 (3.5)	2 (1.7)	2 (1.8)
\geq 18 to <65 years	109 (95.6)	112 (96.6)	108 (97.3)
\geq 65 to <70 years	1 (0.9)	2 (1.7)	1 (0.9)
Patient conditions, $n (\%)^a$			
Hospitalized	29 (25.4)	44 (37.9)	33 (29.7)
Outpatient	49 (43.0)	40 (34.5)	48 (43.2)
Recuperation at home	2 (1.8)	1 (0.9)	0 (0.0)
Recuperation at hotels	34 (29.8)	31 (26.7)	30 (27.0)
Time from onset to randomization, <i>n</i> (%)			
<24 hours	11 (9.6)	2 (1.7)	5 (4.5)
			1

Page 33 of 37

\geq 24 to <48 hours	21 (18.4)	21 (18.1)	24 (21.6)
\geq 48 to <72 hours	23 (20.2)	30 (25.9)	25 (22.5)
\geq 72 to <96 hours	37 (32.5)	38 (32.8)	33 (29.7)
\geq 96 to \leq 120 hours	22 (19.3)	23 (19.8)	24 (21.6)
>120 hours	0 (0.0)	2 (1.7)	0 (0.0)
COVID-19 vaccination history, <i>n</i> (%)	97 (85.1)	97 (83.6)	97 (87.4)
Patients with COVID-19 symptoms, <i>n</i> (%)			
Respiratory symptoms			
Stuffy or runny nose	29 (25.4)	34 (29.3)	26 (23.4)
Sore throat	65 (57.0)	63 (54.3)	54 (48.6)
Shortness of breath (difficulty breathing)	8 (7.0)	8 (6.9)	1 (0.9)
Cough	48 (42.1)	46 (39.7)	49 (44.1)
Systemic symptoms			
Low energy or tiredness	37 (32.5)	42 (36.2)	27 (24.3)
Muscle or body aches	26 (22.8)	19 (16.4)	23 (20.7)
Headache	28 (24.6)	30 (25.9)	24 (21.6)
Chills or shivering	31 (27.2)	20 (17.2)	17 (15.3)
L			1

Page 34 of 37

Feeling hot or feverish	43 (37.7)	41 (35.3)	36 (32.4)
Digestive symptoms			
Nausea	4 (3.5)	5 (4.3)	2 (1.8)
Vomiting	3 (2.6)	3 (2.6)	2 (1.8)
Diarrhea	6 (5.3)	6 (5.2)	8 (7.2)
Sensation disturbance			
Anosmia	16 (14.0)	10 (8.6)	10 (9.0)
Dysgeusia	19 (16.7)	7 (6.0)	9 (8.1)
Total score of 12 COVID-19 symptoms, mean $(SD)^b$	9.9 (5.0)	9.3 (4.5)	8.6 (3.8)
Patients with fever (body temperature \geq 37.0°C), <i>n</i> (%)	45 (39.5)	39 (33.6)	30 (27.0)

^aIn Japan, patients were eligible for enrollment irrespective of treatment settings (inpatient, outpatient, recuperation at home, or recuperation at

designated hotels) because some of them required hospitalization or recuperation for the purpose of isolation or clinical trial participation,

regardless of disease severity, at the time of this research. ${}^{b}n=110$, n=113, and n=110 for the ensited vir 125 mg, ensited vir 250 mg, and placebo groups, respectively.

COVID-19, coronavirus disease 2019; ITT, intention-to-treat; SD, standard deviation.

Statistics	Ensitrelvir 125 mg	Ensitrelvir 250 mg	Placebo
	(N=114)	(N=116)	(N=111)
N	109	113	110
Mean (SD) change from baseline	-5.95 (4.02)	-5.42 (3.70)	-4.92 (3.25)
LS mean (SE) change from baseline assessed by ANCOVA	-5.37 (0.24)	-5.17 (0.23)	-5.12 (0.24)
LS mean (SE) difference in change from baseline versus placebo	-0.24 (0.30)	-0.04 (0.29)	_
95% CI	-0.83 to 0.34	-0.62 to 0.53	_
<i>P</i> -value	0.4171	0.8806	-

Table 2 Time-weighted average change from baseline up to 120 hours in the total score of 12 COVID-19 symptoms (ITT population)

ANCOVA, analysis of covariance; CI, confidence interval; COVID-19, coronavirus disease 2019; ITT, intention-to-treat; LS, least squares; SD,

standard deviation; SE, standard error.

Table 3 Summary of TEAEs (safety analysis population)

Patients with events, <i>n</i> (%)	Ensitrelvir 125 mg	Ensitrelvir 250 mg	Placebo
	(N=140)	(N=140)	(N=141)
Patients with any TEAE	48 (34.3)	60 (42.9)	44 (31.2)
Patients with any treatment-related AE	19 (13.6)	31 (22.1)	7 (5.0)
Patients with any serious TEAE	0 (0.0)	0 (0.0)	2 (1.4)
Patients with TEAEs leading to death	0 (0.0)	0 (0.0)	0 (0.0)
Patients with TEAEs leading to treatment discontinuation	2 (1.4)	0 (0.0)	0 (0.0)
TEAEs occurring in $\geq 2\%$ of patients in either group			
Dyslipidemia	0 (0.0)	3 (2.1)	0 (0.0)
Headache	3 (2.1)	3 (2.1)	0 (0.0)
Diarrhea	2 (1.4)	3 (2.1)	1 (0.7)
Abdominal pain upper	0 (0.0)	0 (0.0)	4 (2.8)
Rash	2 (1.4)	1 (0.7)	3 (2.1)
Back pain	1 (0.7)	3 (2.1)	1 (0.7)
High-density lipoprotein decrease	31 (22.1)	40 (28.6)	5 (3.5)
Blood triglycerides increase	1 (0.7)	9 (6.4)	1 (0.7)

Page	37	of 37
------	----	-------

Blood creatine phosphokinase increase	0 (0.0)	0 (0.0)	4 (2.8)
Treatment-related AEs occurring in ≥5% of patients in either group			
High-density lipoprotein decrease	13 (9.3)	22 (15.7)	0 (0.0)

AE, adverse event; TEAE, treatment-emergent AE.

























